Addex Shareholders Approve All Resolutions at Annual General Meeting
July 01, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
June 06, 2024 01:00 ET
|
Addex Therapeutics
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 -...
Addex Convenes Annual General Meeting 2024
June 05, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
May 31, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
Addex to Present at Bio€quity Europe 2024
May 08, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO,...
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
April 29, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
Addex to Present at the Swiss Biotech Day 2024
April 19, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that...
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
April 18, 2024 01:00 ET
|
Addex Therapeutics
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical...
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
April 11, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that...
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
April 03, 2024 01:00 ET
|
Addex Therapeutics
Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and...